PT  - JOURNAL ARTICLE
AU  - Goonewardena, Sascha N.
AU  - Murthy, Venkatesh L.
TI  - The complete blood count and cardiovascular disease: analyses across six cohorts of 23,370 adults
AID  - 10.1101/2024.10.17.24315694
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.17.24315694
4099  - http://medrxiv.org/content/early/2024/10/18/2024.10.17.24315694.short
4100  - http://medrxiv.org/content/early/2024/10/18/2024.10.17.24315694.full
AB  - Background The complete blood count (CBC) is one of the most commonly performed laboratory studies. Although studies have found associations between the CBC and cardiovascular disease (CVD), there is limited contemporary information regarding the relationship between the CBC and traditional risk factors and their joint association with CVD endpoints.Objective We sought to define the relationships between the CBC and traditional CVD risk factors and their joint association with CVD endpoints in diverse adult populations.Methods We first examined the relationships between the CBC variables (directly and their principal components), traditional CVD risk factors, and mortality in NHANES (n=7843). Next, we validated and extended these findings to more refined CVD endpoints in five additional cohorts (n=15,527).Results We first examined the variance accounted for by common laboratory studies (lipid panel, HbA1c, hs-CRP, and basic metabolic panel) by traditional risk factors in NHANES. With the exception of hemoglobin (Hb)-related components, we found that traditional risk factors accounted for less than 20% of the variance in CBC values, similar to that of lipid parameters. Additionally, in the clinically adjusted model, the CBC was more strongly associated with all-cause mortality than the lipid panel or CRP (p<0.0001). Next, we validated and extended these findings across five additional longitudinal cohorts with a mean follow-up of 16 years to evaluate the association of individual CBC parameters and their principal components with refined CVD endpoints. In the fully adjusted meta-analyses across the five cohorts, several CBC components including the white blood cell (WBC) count, neutrophil (PMN) count, hemoglobin (Hb) level, and an integrated immune cell score, were associated with individual CVD endpoints and a composite CV endpoint (MACE3: incident stroke, MI, and revascularization) with standardized hazard ratios of 1.13 (p=0.002), 1.15 (p=0.0006), 0.82 (p<0.0001), and 2.16 (p<0.0001) respectively.Conclusion This study represents the first systematic examination of the relationship between CBC features and established risk factors, as well as numerous CVD endpoints, in a diverse cohort of 23,370 adults. The findings of this study underscore the potential utility of integrating CBC features into CVD risk assessment and suggest important mechanistic insights into the association between individual CBC components and the genesis of CVD.Competing Interest StatementDr. Goonewardena is supported by VA MERIT grant 1I01CX002560, NIH/NHLBI grant R01HL150392, and the Taubman Medical Research Institute (Wolfe Scholarship). Dr. Murthy owns stock or stock options in General Electric, Amgen, Cardinal Health, Ionetix, Boston Scientific, Merck, Eli Lilly, Johnson and Johnson, Viatris, and Pfizer. He has received research grants and consulting fees from Siemens Medical Imaging. He has served on medical advisory boards for Ionetix. He is a consultant for INVIA Medical Imaging Solutions. Dr. Murthy is supported in part by grants from the National Institute of Diabetes, Digestive, and Kidney Diseases (U01DK123013-03); National Institute on Aging (R01 AG059729); National Heart, Lung and Blood Institute (R01 HL136685); American Heart Association Strategically Focused Research Network grant in Cardiometabolic Disease; and the Melvyn Rubenfire Professorship in Preventive Cardiology.Funding StatementThis study was funded by VA MERIT grant 1I01CX002560; NIH/NHLBI grant R01HL150392; National Institute of Diabetes, Digestive, and Kidney Diseases (U01DK123013-03); National Institute on Aging (R01 AG059729); and National Heart, Lung and Blood Institute (R01 HL136685). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of Michigan gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.ASCVDatherosclerotic cardiovascular diseaseBMPbasic metabolic panelCACcoronary artery calcificationCARDIACoronary Artery Risk Development in Young AdultsCBCComplete blood countCCcirculating cellsCMcirculating mediatorsCVDcardiovascular diseaseCRICchronic renal insufficiency cohortCRPC-reactive proteinHbA1chemoglobin A1cHDLhigh-density lipoproteinHbhemoglobinLDLlow-density lipoproteinMESAMulti-Ethnic Study of AtherosclerosisMImyocardial infarctionNHANESNational Health and Nutrition Examination SurveyPCAprincipal component analysisPMNneutrophilRBCred blood cellWBCwhite blood cell